Skip to content

Remimazolam vs Midazolam study

Comparative study on the efficacy and recovery of Remimazolam and Midazolam in the sedation for the patients undergoing gastrointestinal endoscopy - RECOVER Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs071240062
Enrollment
80
Registered
2024-09-26
Start date
2024-09-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing upper gastrointestinal or colonoscopy with sedation. Upper gastrointestinal endoscopy, Colonoscopy

Interventions

Sponsors

Yamaguchi Daisuke
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients whose written consent was already obtained with free will. 2) Japanese patients between the ages of 18 and 80 years at the time of obtaining consent. 3) Patients scheduled to undergo upper gastrointestinal endoscopy or colonoscopy with sedation.

Exclusion criteria

Exclusion criteria: 1) Patients scheduled to undergo endoscopic procedures. 2) Patients with a history of surgery on the upper and lower digestive tract. 3) Patients on dialysis. 4) Patients consuming more than 60 grams of alcohol per day. 5) Patients who have severe liver damage. 6) Patients with III/IV class of ASA-PS. 7) Patients who can not independently walk. 8) Patients who regularly use benzodiazepines, analgesics or central nervous system depressant. 9) Patients who have sedatives during 4 weeks before the time of obtaining consent. 10) Patients who have acute angle-closure glaucoma. 11) Patients who have myasthenia gravis. 12) Patients who are in pregnancy or under breast feeding. 13) Patients with a history of hypersensitivity to benzodiazepines or flumazenil, and patients with conditions or symptoms for which administration of these drugs is contraindicated. 14) Patients whom the investigator determines to be inappropriate for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
The percentage of patients who have good ambulation in 5 minutes after endoscopy.

Secondary

MeasureTime frame
(1) Success rate of sedation with MOAA/S score under 4 before endoscopy. (2) Remimazolam and midazolam doses required to obtain sedation (MOAA/S score under 4) prior to endoscopy. (3) Total remimazolam and midazolam dose required to complete the endscopic procedure. (4) The time until the start of endscopy (MOAA/S score under 4) from the start of sedation. (5) The time until good ambulation (MOAA/S score 5) from the end of endoscopy. (6) Walking ability:The total time until good ambulation (MOAA/S score 5) from the end of endoscopy (include rest time for difficulty walking). (7) Patient evaluation score: Patient satisfaction is rated on a 5-point scale from 1 to 5 using a survey form and recorded. (8) Physician evaluation score: Physician satisfaction is rated and recorded on a 5-point scale of 1 to 5 using the questionnaire.

Contacts

Public ContactDaisuke Yamaguchi

Saga University Hospital

daisukehawks@gmail.com+81-952-34-2361

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026